Cargando…
Triggering Innate Immune Receptors as New Therapies in Alzheimer’s Disease and Multiple Sclerosis
Multiple sclerosis and Alzheimer’s disease are two complex neurodegenerative diseases involving the immune system. So far, available treatments provide at best mild improvements to patients’ conditions. For decades now, a new set of molecules have been used to modulate and regulate the innate immuni...
Autores principales: | Piec, Pierre-Alexandre, Pons, Vincent, Rivest, Serge |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393987/ https://www.ncbi.nlm.nih.gov/pubmed/34440933 http://dx.doi.org/10.3390/cells10082164 |
Ejemplares similares
-
Muramyl Dipeptide Administration Delays Alzheimer’s Disease Physiopathology via NOD2 Receptors
por: Piec, Pierre-Alexandre, et al.
Publicado: (2022) -
Innate Immune Cells: Monocytes, Monocyte-Derived Macrophages and Microglia as Therapeutic Targets for Alzheimer’s Disease and Multiple Sclerosis
por: Fani Maleki, Adham, et al.
Publicado: (2019) -
Conditional genetic deletion of CSF1 receptor in microglia ameliorates the physiopathology of Alzheimer’s disease
por: Pons, Vincent, et al.
Publicado: (2021) -
Inhibiting nighttime melatonin and boosting cortisol increase patrolling monocytes, phagocytosis, and myelination in a murine model of multiple sclerosis
por: Ghareghani, Majid, et al.
Publicado: (2023) -
Author Correction: Inhibiting nighttime melatonin and boosting cortisol increase patrolling monocytes, phagocytosis, and myelination in a murine model of multiple sclerosis
por: Ghareghani, Majid, et al.
Publicado: (2023)